CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data
CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data WASHINGTON (dpa-AFX) - Today's Daily Dose brings you news about BioCryst's update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, Supernus' phase III study results of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder, and Spectrum's progress with Poziotinib for non-small cell lung cancer. Read on. 1. BioCryst Not to Pursue COVID-19 indication for antiviral G...
Source: finanznachrichten.de